ESTRO 2024 - Abstract Book

S2047

Clinical - Paediatric

ESTRO 2024

Medulloblastoma

146 (100%)

22 (19%)

Craniopharyngioma

-

13 (11%)

Ependymoma

-

13 (11%)

Germ cell tumour

-

12 (10%)

High grade glioma

-

20 (17%)

Low grade glioma Other

- -

15 (13%) 20 (17%)

Risk status (medulloblastoma)

High

33 (28%)

14 (74%)

Standard Unknown

83 (72%) 30 9 (3 – 22) 30

5 (26%) 96

Age at treatment (years) Unknown

16 (2 – 30) 0

Hydrocephalus

Yes

92 (84%)

47 (43%)

No Unknown

18 (16%) 36

62 (57%) 6

Shunt for hydrocephalus treatment

Yes

36 (33%)

15 (14%)

No Unknown

74 (67%) 36

89 (86%) 0

Chemotherapy

Yes

146 (100%)

55 (50%)

No Unknown

0 0

56 (50%) 4

Table 1. Patient demographic, treatment, and outcome data for the two centres. One cohort is only medulloblastoma patients, whereas the other is mixed diagnosis. Cohort A is also younger and reports different treatment and outcome characteristics. In Figure 1, the significant regions identified in IBDM are shown and volumetric overlap with anatomy reported. The 99% significance level overlaps with the pituitary, brainstem, and white matter in cohorts A and B, but does not overlap with the hypothalamus in either cohort. The hypothalamus is covered by the 95% significance level in Cohort A but not Cohort B.